Representations of IC. IC hereby represents to Collaborator that: 9.1.1 IC has the requisite power and authority to enter into this CRADA and to perform according to its terms, and that IC’s official signing this CRADA has NCI DCTD CRADA model adopted October 14, 2011 Case Ref. No. 00-0-00000 Page 23 of 33 Confidential authority to do so. 9.1.2 To the best of its knowledge and belief, neither IC nor any of its personnel involved in this CRADA is presently subject to debarment or suspension by any agency of the Government that would directly affect its performance of the CRADA. Should IC become aware that any of its personnel involved in this CRADA are debarred or suspended during the term of this CRADA, IC will notify Collaborator within thirty (30) days.
Appears in 3 contracts
Samples: Cooperative Research and Development Agreement, Cooperative Research and Development Agreement (Tracon Pharmaceuticals, Inc.), Cooperative Research and Development Agreement (Tracon Pharmaceuticals Inc)
Representations of IC. IC hereby represents to Collaborator that:
9.1.1 IC has the requisite power and authority to enter into this CRADA and to perform according to its terms, and that IC’s official signing this CRADA has NCI DCTD authority to do so. PHS ICT-CRADA model adopted October 14, 2011 Case Agreement Ref. No. 00-0-00000 MODEL ADOPTED June 18, 2009 Page 23 14 of 33 Confidential authority to do so.25 Revised May 15, 2014
9.1.2 To the best of its knowledge and belief, neither IC nor any of its personnel involved in this CRADA is presently subject to debarment or suspension by any agency of the Government that which would directly affect its performance of the CRADA. Should IC become aware that or any of its personnel involved in this CRADA are be debarred or suspended during the term of this CRADA, IC will notify Collaborator within thirty (30) daysdays of receipt of final notice.
Appears in 1 contract
Samples: Cooperative Research and Development Agreement (Ziopharm Oncology Inc)